Nexera X2 — X-ceptional insights - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Nexera X2 – X-ceptional insights

Ultra-high sensitivity, expanded flexibility, increased stability and robustness - the new Nexera X2 UHPLC system targets routine analysis and applications in highly regulated environments demanding complex system setups.

System flexibility
The system flexibility is based on software features which control multiple gradients in a single system. This enables automated solvent blending on each pump in a binary gradient setup. The software has been adapted to meet the requirements for use in highly regulated environments.

Stability in gradient use has been improved by pump side modifications. Furthermore, design changes on inlet valve and degassing unit minimize air bubbles passing through the flow line and reduce their negative effects on stability and performance. For addressing specific applications, additional micro reactor based mixing devices can be selected accordingly. A newly designed low volume quaternary option reduces the system volume to meet UHPLC needs while enabling a better inter-system method transfer.

The new SPD-M30A photodiode array detector is perfectly suited ultra-high sensitive applications using a capillary cell with low dispersion. Total reflection and a high energy deuterium lamp guarantee a low noise level. A novel temperature control principle decreases baseline drift and offers improved reliability even under changing environment conditions. Together with ultra-high speed data acquisition, software features which maximize resolution on the PDA while enabling peak deconvolution squeeze the maximum information out of a single analysis.

For more information please visit

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FindPharma Custom Search

Click here